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PHE12 of deacetyl-thymosin b4 is one of the
structural essentials for restorative effect on the
impaired blastogenic response of uraemic T-lym-
phocytes. In order to evaluate the functional roles
of this phenyl group in the restorative effect
on impaired T-lymphocytes, two analogues, [1-
Nal12]deacetyl-thymosin b4 and [Cha12]deacetyl-
thymosin b4, were synthesized by a solid-phase
method and evaluated for restorative effect on the
impaired blastogenic response of uraemic T-lym-
phocytes. The results indicated that [1-Nal12]de-
acetyl-thymosin b4 which had a bulky naphthyl
ring showed a stronger restorative effect than
that of deacetyl-thymosin b4, but it was slightly
weaker than that of [Phe(4F)12]deacetyl-thymosin
b4. However, [Cha12]deacetyl-thymosin b4 showed
no restorative effect on the impaired blastogenic
response of uraemic T-lymphocytes.
Key words: Blastogenic response, Deacetyl-thymosin
b4 analogue synthesis, Impaired T-lymphocyte, Restor-
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Abbreviations
Boc, tert-butyloxycarbonyl; tBu, tert-butyl; DMF ,
N,N-dimethylformamide; TFA, tri￿uoroacetic
acid; Fmoc, 9-￿uorenylmethoxycarbonyl; HOBT ,
1-hydroxybenzotriazole; DCC, dicyclohexylcar-
bodiimide; HBF4, tetra￿uoroboric acid; EDT ,
ethane-1,2-dithiol; AcOH, acetic acid; HPLC,
high-performance liquid chromatography; TLC,
thin-layer chromatography; 1-Nal, 1-naphthyla-
lanine; Cha, cyclohexylalanine; PHA, phyto-
haemagglutinin; RPMI, Rosewell Park Memorial
Institute; SDS, sodium dodecyl sulphate; PBS,
phosphate-buffered saline; FCS, fetal calf serum;
FAB-MS, fast atom bombardment mass spectro-
metry; Pam, phenylacetoamido-methyl; Ac, ace-
tyl.
Introduction
The impairment of immunological responsive-
ness in uraemic patients is well known. All
aspects of the immune response appear to be
affected by the uraemic state. The numbers,
subpopulations and reactivities of circulating
lymphocytes may be altered by uraemia.1,2 This
impairment has been implicated in easy suscept-
ibility to infections and increased incidence of
malignancy.
Thymosin b4, an N-terminal acetylated pep-
tide containing 43 amino acid residues, was ￿rst
isolated from calf thymus by Low et al.3 and has
the following amino acid sequence: Ac-Ser-Asp-
Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-
Ser-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-
Pro-Ser-Lys-Leu-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-
Gln-Ala-Gly-Glu-Ser-OH. This peptide exhibits
several biological activities that are important
for maturation and functioning of the immune
systems.4
Previously5 7 we reported syntheses of deace-
tyl-thymosin b4 and its fragments and that some
of the fragments could have a restorative effect
on the impaired cell-mediated immunological
functions. We also noticed that the acetyl group
at the N-terminal serine residue of thymosin b4,
is not required for the restorative effect on the
impaired cell-mediated immunological func-
tions.5
In an earlier paper,8 we reported that the
synthetic [Phe(4F)12]deacetyl-thymosin b4 ex-
hibited stronger restorative effect on the im-
paired blastogenic response of T -lymphocytes
isolated from uraemic patients than that of our
synthetic deacetyl-thymosin b4. In this study,
the strong electron-withdrawing ￿uoride atom
on the para-position of the aromatic ring results
in an analogue that possesses stronger activity
than that of the parent molecule.8 This result
seems to suggest that modi￿cation of the Phe
residue of thymosin b4 could produce more
potent analogues capable of a restorative effect
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cytes.
The purpose of the present study was to
synthesize two thymosin b4 analogues, [1-
Nal12]deacetyl-thymosin b4 and [Cha12]deacetyl-
thymosin b4 by the solid-phase method and to
compare the restorative effect of these two
analogues on the impaired blastogenic response
of uraemic T -lymphocytes.
Materials and Methods
Fmoc-amino acid derivatives and Fmoc-Ser
(tBu)-Pam-resin (0.64 mmol/g, 100± 200 mesh)
were purchased from Kokusan Chemical Works
Ltd (Japan), Watanabe Chemical Industries Ltd
(Japan), Peptide Institute Inc (Japan) and Sigma
Chemical Co. (USA). TLC was effected with
silica gel (Kieselgel 60F254, Merck) on precoated
aluminium sheets using n-BuOH-AcOH-pyridine-
H 2) 4:1:1:2 as a solvent system. Analytical
HPLC and amino acid analysis were conducted
with a Shimadzu LC-6A and Hitachi 835A,
respectively. The FAB-MS spectrum was ob-
tained on a VG analytical 2AB-2SEQ spectro-
meter equipped with the 11-250J data system.
Solid-phase peptide synthesis
Peptide synthesis was performed manually by
the stepwise solid-phase method with a hand-
made peptide synthesizer, using the base-labile
Fmoc group for protecting the a-amino groups,
and such acid-labile groups as the tBu for the
hydroxy and carboxy groups, the Boc for the e-
amino groups of Lys, and the sulphoxide for
Met. The peptide was assembled on Fmoc-Ser
(tBu)-Pam-resin. The Emoc group was removed
with 30%piperidine in DMF . Elongation of the
peptide chain was carried out by the DCC-
HOBT method in CH 2Cl2-DMF (1:1) or in N-
methyl-2-pyrrolidone. The coupling reaction
and deprotection of the Fmoc group were
monitored by the ninhydrin test. The general
procedure for each synthetic cycle (as a starting
mateial 0.64 mmol/g of Fmoc-Ser(tBu)-Pam-
resin: 400 mg) was: (1) CH 2Cl2 wash (twice);
(2) DMF wash (twice); (3) deprotect: DMF-
piperidine (7:3) for 20 min; (4) DMF wash
(twice); (5) dioxane-water (2:1) wash (twice);
(6) DMF wash (three times); (7) CH 2Cl2 wash
(three times); (8) addition of 3 eq Fmoc-amino
acid, HOBT , and DCC in CH 2Cl2-DMF (1:1) or
N-methyl-2-pyrrolidone; (9) add 1.0 ml of diiso-
propylethylamine in CH 2Cl2; (10) reaction for
120 min; (11) recoupled if necessary by repeat-
ing steps 7± 10; (12) DMF wash (three times);
(13) isopropanol wash (three times); (14)
CH 2Cl2 wash (four times). Whenever the ninhy-
drin test was still slightly positive, even after
three couplings, the remaining unreacted amino
groups were acetylated with Ac2O-pyridine in
DMF . The peptide resin (200 mg) was treated
with 2 M HBF4-thioanisole in TFA (7ml) in the
presence of m-cresol (218 ml, 100 eq) and EDT
(524 ml, 300 eq) at 48 Cfor 90 min.
After the deprotection, the resin was removed
by ￿ltration and the ￿ltrate was evaporated
under reduced pressure and the residue was
solidi￿ed by addition of anhydrous peroxide
free ether to give a crude peptide. The resulting
powder was dissolved in H 2O (6 ml). The
solution was treated with Amberlite CG-4B
(acetate form, approximately 3 g) for 30 min,
and ￿ltered by suction and evaporated in
vacuo. The residue was dissolved in H 2O
(10 ml). The solution, after addition of dithio-
threitol (20 mg), was incubated at 608 C under
N 2 gas for 36 h. The solvent was evaporated off
in vacuo and the residue was dissolved in a
small amount of 1%AcOHand then applied to a
column of Sephadex G-25 (2.3 3 95 cm), which
was eluted with the same solvent. Individual
fractions (5 ml each) were collected and absor-
bancy at 230 nm was determined for each
fraction. The fractions corresponding to the
front main peak were combined and the solvent
was removed by lyophilization. The peptide
was further puri￿ed by semi-preparative PR-
HPLC. The semi-preparative PR-HPLC was
performed on a Nucleosil C18 column
(250 3 10 mm I.D.; 7 mm particle size; Macherey
Nagel). Solvent A was 0.05%TFA in water and
solvent B was 60%acetonitrile in solvent A. A
linear gradient was applied from 10 to 50% B
during 50 min, at a ￿ow rate of 3.0 ml/min.
Detection of the peptide was set at 230 nm.
The major peak was lyophilized to give the
puri￿ed product. [1-Nal12]deacetyl-thymosin b4;
20.3 mg (20% , calculated from the starting C-
terminal amino acid). [Cha12]deacetyl-thymosin
b4; 22.6 mg (23% , calculated from the starting
C-terminal amino acid) (Fig. 1).
Patient selection
Three uraemic patients who needed dialysis
treatment three times a week and were suffer-
ing from recurrent infectious diseases (pneumo-
nia and tuberculosis) were selected. Exam-
ination of cellular immunocompetence of these
patients revealed a signi￿cant decrease in blast-
formation by PHA. 3H-thymidine incorporation
values of these patients were 11826, 12042
and 12153 cpm respectively (normal values:
41195± 42 659 cpm).
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mic patients for the ￿uorometric blast-formation
test. Venous blood samples from three healthy
donors were used as a control. The ￿uores-
cence excitation spectrum was measured with
an Oyo-Bunko ULOG-FLOUSPEC 11A ￿uoro-
meter. Kits for the ￿uorometric blast-formation
test were purchased from Japan Immunore-
search Laboratories Co. Ltd (Japan).
Fluorometric blast-formation test
A 3 ml aliquot of venous blood was drawn into
a syringe containing 25 U/ml of heparin and
then mixed with 3 ml of PBS. Lymphocytes
were isolated in a Hypaque-Ficoll gradient.
Isolated lymphocytes were adjusted to
1 0 3 106/ml with PBS. The lymphocytes were
cultured in 0.5 ml of RPMI 1640 (Gibco) with
10% FCS (Dainippon Pharmaceutical Co.) in
microplates. Cultures of each combination were
incubated at 378 C in the presence of one of the
peptides in a humidi￿ed atmosphere of 5%CO2
in air or 12 h and then PHA (0.125% ) was added
to each well and incubation was continued
under the same conditions for 60 h. Lympho-
cytes in each well were transferred into a test
tube and centrifuged for 10 min at 240 g, then
the supernatant was removed. A 2 ml aliquot of
0.125% SDS was added to the residue and
stirred for 20 min at room temperature; lympho-
cytes were completely destroyed and solubilized
by this procedure. Ethidium bromide solution
(2 ml) was added to the above solution and the
mixture was stirred for 15 min at room tempera-
ture. The ￿uorescence excitation spectrum was
measured as previously described.7
Results
In order to construct the peptide chain, the
Fmoc-based solid-phase method was employed.
Fmoc-Ser(tBu)-Pam-resin was placed in the reac-
tion vessel and the combination of piperidine
treatment and DCC plus HOBT procedure
served to elongate the peptide chain manually
according to the usual method.
We encountered no serious dif￿culties during
the elongation of the entire sequences of the
two analogues, although the double coupling
procedure was employed when the resin be-
came positive to the ninhydrin test, after a
single coupling. The coupling cycle included a
capping step with acetic anhydride (5min) to
prevent the formation of deleted sequences.
The amino acid compositions of the protected
peptide resins thus assembled were in good
agreement with those predicted by theory after
acid hydrolysis with 12 N HCl-proprionic acid
(1:1). The protected peptide resins thus ob-
tained were then treated with 2 MHBF4-thioani-
sole in TFA at 48 C for 90 min to cleave the
peptide chain from the resin and at the same
time to remove all side-chain protecting groups
employed. The Met(O) residue was reduced
back to Met in two steps, ￿rstly with 2 MHBF4-
thioanisole in TFA during the above acid treat-
ment, and secondly with dithiothreitol during
incubation of the unprotected peptide.
The crude peptides thus obtained were then
successively puri￿ed by gel-￿ltration on Sepha-
dex G-25 and semi-preparative HPLC. The two
puri￿ed peptides exhibited single peaks on
analytical HPLC. The two products possessed
amino acids in ratios consistent with those
predicted from the sequences of the two
analogues after acid hydrolysis. The homogene-
ity of the peptides was checked by TLC, HPLC,
amino acid analysis after 6 N HCl hydrolysis,
and FAB-MS spectrometry. Physicochemical data
for the synthetic analogues are shown in Tables
1 and 2.
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Fig. 1. HPLC pro® les of (A) [1-Nal12]deacetyl-thymosin b4
and (B) [Cha12]deacetyl-thymosin b4.
Table 1. Characterization of synthetic thymosin b4 analogues
Peptide Yielda
(%)
[a]21
D
(c 0.5, 1% AcOH)
TLCb
Rf
FAB-MSc
(MH )
[1-Nal12]deacetyl-thymosin b4 20 84.98 0.09 4971.13
[Cha12]deacetyl-thymosin b4 23 79.58 0.11 4927.32
aFinal yield after deblocking and puri® cation starting from Fmoc-Ser(tBu)-Pam-resin.
bSee the experimental section.
cFound values were in agreement with calculated values.
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deacetyl-thymosin b4, [Phe(4F)12]deacetyl-thy-
mosin b4, [1-Nal12]deacetyl-thymosin b4 and
[Cha12]deacetyl-thymosin b4 were examined by
the JIMRO (Japan Immunoresearch Laboratories
Ltd) ￿uorometric blast-formation test. Re-
sponses of T -lymphocytes to mitogenic stimula-
tion were signi￿cantly lower in uraemic
patients that were those of normal persons. The
in vitro effect of the synthetic peptides on the
impaired PHA response of T -lymphocytes from
uraemic patients is shown in Table 3.
Discussion
Comparison of the stimulation index (SI) values
of the blastogenic transformation of T -lympho-
cytes into lymphoblasts with mitotic activity
upon PHA stimulation shows that in the case of
the uraemic patients investigated, the synthetic
analogue, [1-Nal12]deacetyl-thymosin b4 which
had a bulky naphthyl ring exhibited stronger
restorative activity than that of our synthetic
deacetyl-thymosin b4, but it was a little bit
weaker than that of [Phe(4F)12]deacetyl-thymo-
sin b4. However, the synthetic [Cha12]deacetyl-
thymosin b4 had no restorative effect even at a
much higher concentration (Table 4).
Those results exhibited that not only 4-￿uor-
ophenyl ring of deacetyl-thymosin b4 but also
more bulky naphthyl ring of deacetyl-thymosin
b4 could bind with receptors of T -lymphocytes
more strongly than a phenyl ring of deacetyl-
thymosin b4. On the contrary, another analogue,
[Cha12]deacetyl-thymosin b4 which contains an
aliphatic ring at position of 12 instead of an
aromatic ring showed no restorative effect. This
result seems to suggest that aromaticity at
position of 12 of thymosin b4 plays signi￿cant
roles for restorative activity on impaired blasto-
genic response of T -lymphocytes.
Table 2. Amino acid analysis of synthetic thymosin b4 analoguesa
Peptide Gly Ala Leu Ile Pro Ser Thr Metb Lys Asp Glu 1-Nal Cha
[1-Nal12]deacetyl-thymosin b4 1.00 1.96 2.01 1.90 2.89 3.87 2.91 0.92 8.96 3.87 10.38 0.94
[Cha12]deacetyl-thymosin b4 1.00 1.92 1.95 1.94 2.90 3.96 2.85 0.93 9.02 389 10.81 0.96
aAfter acid hydrolysis with 6 N HCl at 1268 C for 25 h.
bMet Met(O).
Table 3. Effects of synthetic deacetyl-thymosin b4 and its analogues on the impaired
PHA stimulation of uraemic T-lymphocytes
Peptide No. of
determinations
Dose (mg/ml) SIa,b
Ð c 3 Ð 274.2 49.8
Ð d 3 Ð 114.3 48.7f
Deacetyl-thymosin b4
d,e 3 0.1 115.1 49.3
Deacetyl-thymosin b4
d,e 3 1.0 198.3 50.1g
[Phe(4F)12]deacetyl-thymosin b4
d,e 3 0.1 190.6 48.5g
[Phe(4F)12]deacetyl-thymosin b4
d,e 3 1.0 230.5 48.3g
[1-Nal12]deacetyl-thymosin b4
d,e 3 0.1 179.7 49.6g
[1-Nal12]deacetyl-thymosin b4
d,e 3 1.0 216.8 48.4g
[Cha12]deacetyl-thymosin b4
d,e 3 1.0 117.9 49.0
[Cha12]deacetyl-thymosin b4
d,e 3 10.0 115.3 48.9
aEach value represents the mean SD of triplicate measurements.
bSI (stimulation index) was calculated according to the following formula: SI
(I2 I0) (I1 I0) 3 100, where I2 is mean ¯ uorescence intensity of PHA-activated lymphocytes, I1
is mean ¯ uorescence intensity of PHA-nonactivated lymphocytes and I0 is mean ¯ uorescence
intensity of ethidium bromide.
cNormal venous lymphocytes.
dUraemic patients’ lymphocytes.
eIncubation was carried out at 378 C in a humidi® ed atmosphere of 5% CO2 in air for 12 h in the
presence of each peptide.
fP , 0.03, when compared with the normal subject using Student’s t-test.
gP , 0.01, when compared with the uraemic patients using Student’s t-test.
Table 4. Relative potencies of synthetic deacetyl-thymosin
b4 and its analogues on the impaired PHA stimulation of T-
lymphocytes of uraemic patients
Peptide Relative potency
(molar basis)
Deacetyl-thymosin b4 1.00
[Phe(4F)12]deacetyl-thymosin b4 10.48
[1-Nal12]deacetyl-thymosin b4 9.86
[Cha12]deacetyl-thymosin b4 Ð
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